This page uses content from Wikipedia and is licensed under CC BY-SA.

Nemorexant

Nemorexant
Nemorexant.svg
Clinical data
SynonymsACT-541468
Routes of
administration
By mouth
Drug classOrexin antagonist
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H23ClN6O2
Molar mass450.927 g/mol g·mol−1
3D model (JSmol)

Nemorexant, now called Daridorexant (developmental code name ACT-541468) is a dual orexin receptor antagonist (DORA) which was originated by Actelion Pharmaceuticals and is under development by Idorsia Pharmaceuticals for the treatment of insomnia.[1][2] It acts as a selective dual antagonist of the orexin receptors OX1 and OX2.[1][2] As of June 2018, nemorexant is in phase III clinical trials for the treatment of insomnia.[1]

See also

References

  1. ^ a b c [adisinsight.springer.com]
  2. ^ a b Equihua-Benítez AC, Guzmán-Vásquez K, Drucker-Colín R (July 2017). "Understanding sleep-wake mechanisms and drug discovery". Expert Opin Drug Discov. 12 (7): 643–657. doi:10.1080/17460441.2017.1329818. PMID 28511597.

External links